Epidemiology of Chikungunya in the Americas
Journal of Infectious Diseases December 15, 2016 V.214 Suppl 5 S441-S44
Sergio Yactayo, J. Erin Staples, Véronique Millot, Laurence Cibrelus, and Pilar Ramon-Pardo
1Department of Pandemic and Epidemic Diseases, World Health Organization, Geneva, Switzerland
2Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado
3Department of International Health Regulations, Pan American Health Organization/World Health Organization, Washington D.C.
Chikungunya virus (CHIKV) emerged in the Americas in late 2013 to cause substantial acute and chronic morbidity.
About 1.1 million cases of chikungunya were reported within a year, including severe cases and deaths.
The burden of chikungunya is unclear owing to inadequate disease surveillance and underdiagnosis. Virus evolution, globalization, and climate change may further CHIKV spread.
No approved vaccine or antiviral therapeutics exist. Early detection and appropriate management could reduce the burden of severe atypical and chronic arthritic disease.
Improved surveillance and risk assessment are needed to mitigate the impact of chikungunya.
Entry filed under: Biología Molecular, Epidemiología, FIEBRE en el POST-VIAJE, FIEBRE y RASH, Infecciones emergentes, Infecciones virales, Medicina del viajero, Metodos diagnosticos, Update, Zoonosis.
Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000–2013 Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy